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Parkinson’s disease (PD) is associated with the accumulation of alpha-
synuclein (aSyn) in intracellular inclusions known as Lewy bodies and
Lewy neurites. Under physiological conditions, aSyn is found at the presy-
naptic terminal and exists in a dynamic equilibrium between soluble, mem-
brane-associated and aggregated forms. Emerging evidence suggests that,
under pathological conditions, aSyn begins to accumulate and acquire a
toxic function at the synapse, impairing their normal function and connec-
tivity. However, the precise molecular mechanisms linking aSyn accumula-
tion and synaptic dysfunction are still elusive. Here, we provide an
overview of our current findings and discuss the hypothesis that certain
aSyn aggregates may interact with proteins with whom aSyn normally does
not interact with, thereby trapping them and preventing them from per-
forming their normal functions in the cell. We posit that such abnormal
interactions start to occur during the prodromal stages of PD, eventually
resulting in the overt manifestation of clinical features. Therefore, under-
standing the nature and behaviour of toxic aSyn species and their contribu-
tion to aSyn-mediated toxicity is crucial for the development of therapeutic
strategies capable of modifying disease progression in PD and other synu-
cleinopathies.
Introduction
Parkinson’s disease (PD) and other synucleinopathies are
neurodegenerative diseases characterized by the presence
of intraneuronal inclusions known as Lewy bodies (LBs)
and Lewy neurites (LNs). These inclusions are composed
primarily of alpha-synuclein (aSyn), but they also con-
tain neurofilaments, ubiquitin, synphilin-1, torsinA and
heat shock proteins, among other components [1–3].
aSyn is a small protein of 140 amino acids that
belongs to the synuclein family. It is abundant in neu-
rons of the mammalian brain, where it localizes pre-
dominantly in presynaptic terminals [4–6]. The precise
function of aSyn is still unknown but it is known to
interact with various proteins, like actin [7,8], tubulin,
synphilin-1, microtubule-associated protein tau,
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tyrosine hydroxylase, protein kinase c or Bcl-2-associ-
ated death protein [9]. aSyn is involved in the mainte-
nance of cell structure and protein trafficking via its
interactions with diverse cytoskeletal proteins [10–13].
It is also involved in transmembrane transport and in
the formation of synaptic vesicles [14–16], in stabilizing
the effects of SNARE-complex assembly [17,18] and in
the modulation of synaptic functions [19–22]. As an
intrinsically disordered protein, that can adopt differ-
ent conformations, aSyn may also behave like a hub
within protein interaction networks, interacting and
influencing, directly or indirectly, other partners.
When overexpressed in model systems, aSyn can
aggregate and affect mitochondrial calcium homeosta-
sis [23], and protein import [24] and turnover [25]. In
some models, overexpression promotes cytotoxicity,
impairs autophagy and mitochondrial processes due to
the generation of reactive oxygen species (ROS),
increases sensibility to oxidative stress, compromises
vesicular transport and disrupts the trafficking between
the endoplasmic reticulum (ER) and Golgi [26–32].
Microtubules are important structures for the intra-
cellular transport of molecules in the cytosol, and also
for the integrity of cell shape. In rat, primary neurons
infected with viruses encoding for aSyn [33] exhibit
neurite degeneration and membrane blebbing, consis-
tent with detrimental effects of aSyn on tubulin poly-
merization [34].
aSyn can also mediate the cytoplasmic retention of
DNA methyltransferase 1 (Dnmt1), resulting in DNA
hypomethylation and up-regulation of SNCA and
other PD-related genes. In human postmortem brains
of PD and/or dementia with Lewy body (DLB)
patients, the reduction of nuclear levels of Dnmt1 and
DNA methylation [35], the accumulation of Elk-1
(phosphorylated transcription factor) within aSyn glial
cytoplasmic inclusions [36–38] and cytoplasmic aggre-
gates of phospho-CREB [39,40] were also reported.
All of these cellular pathologies are likely to
contribute to the onset and development of neurode-
generation. Nevertheless, the precise trigger(s) of
pathogenesis in PD and other synucleinopathies
remain unclear.
Parkinson’s disease as a synaptopathy
In PD and other neurodegenerative diseases, synaptic
dysfunction is thought to be an early event that corre-
lates with the manifestation of nonmotor symptoms
[41], while later stages of the disease are characterized
by neurodegeneration and cell loss [42–44]. Thus,
synaptic dysfunction might be considered a prodromal
stage of cellular pathologies that is then followed by
axonal abnormalities, leading to the degenerative loss
of neuronal somas [41,45–54].
aSyn-rich LB inclusions are present not only in neu-
ronal cell bodies but also, and firstly, in axonal pro-
cesses [55]. More recent studies reported aSyn in
axonal dystrophic neurites in the striatum of PD [56]
and DLB patients [57]. These studies suggest that
synucleinopathy occurs in presynaptic terminals and
axons, which goes in line with the predominant local-
ization of aSyn in presynaptic terminals [4–6]. These
early phenotypes can be attributed to the accumulation
of toxic aSyn species within synapses, or the trapping
of synaptic proteins by aSyn, ultimately leading to a
process of dying back-like neurodegeneration.
Under physiological conditions, aSyn functions in
its native conformation, possibly as a monomer. When
the levels of aSyn start to increase, such as due to
changes in its turnover, due to a decline in age-associ-
ated proteostasis or because of the effect of post-trans-
lational modifications [58,59], aSyn may gain
abnormal properties and form toxic species. Among
these toxic species, oligomers and fibrils are thought to
play a key role in pathogenesis in synucleinopathies.
These species can accumulate at presynaptic terminals,
affect neurotransmitter release and synaptic transmis-
sion and, ultimately, cause synaptic dysfunction, lead-
ing to loss of neuronal connections and subsequent
neuronal death (Fig. 1).
aSyn overexpression, which may potentiate the for-
mation of toxic species, has been also shown to induce
severe mitochondrial deficits, including fragmentation
[31], mitophagy [60] and impaired mitochondrial pro-
tein import [24]. These are thought to be relevant for
disease onset. Consistent with functional synaptic
alterations at early stages of PD and other synucle-
inopathies, aSyn-induced mitochondrial impairment in
the nigrostriatal system seems to start in synaptic
mitochondria prior to the onset of generalized mito-
chondrial dysfunction in other parts of the neuronal
cell.
aSyn interacts with the HSP10
chaperonin
In addition to the cytosol, aSyn has also been detected
in mitochondria [61], where it affects, for example, res-
piratory chain complex activity [62,63]. aSyn interacts
with several synaptic and mitochondrial proteins [64]
and affects the function of these compartments
[24,25,27,50,65–67].
Abnormalities in mitochondrial lipids and impair-
ments in the electron transport chain were described in
aSyn knockout mice. In addition, impairment in
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mitochondrial complex I activity and increased ROS
production in mitochondria are associated with the
accumulation of wild-type aSyn in human dopaminer-
gic neurons in culture and in postmortem PD brain tis-
sue [63]. These findings suggest that both loss of
function and aggregation of aSyn may affect mito-
chondrial function [62] and, thereby, affect neuronal
homeostasis. Nevertheless, the exact impact of aSyn in
striatal synaptosomal mitochondria is still unclear.
One of the proteins affected by aSyn is the 10 kDa
heat shock protein (HSP10). HSP10 is a major hub
protein in cellular interactions [68] that also plays an
important role in regulating mitochondrial functions
such as respiration, removal of ROS and maintaining
mitochondrial membrane potential [69]. Together with
the 60 kDa heat shock protein (HSP60), HSP10 forms
asymmetric or symmetric complexes in mitochondria
(Fig. 2). Interestingly, the asymmetric complex has
decreased folding capacity, while the formation of the
symmetric complex is limited by the levels of HSP10
[70]. A reduction in the function of HSP10/HSP60
Fig. 1. Neurodegeneration associated with the accumulation of aSyn in presynaptic terminals. (A) Under physiological conditions, aSyn
functions in its native conformation, possibly as a monomer, and localizes predominantly in presynaptic terminals. (B) Toxic aSyn species,
generally known as oligomers and PFF, start to form and accumulate at the presynaptic terminal, leading to alterations in synaptic
transmission and promoting synaptic dysfunction. (C) Ultimately, the accumulation of toxic species of aSyn leads to a process of dying back-
like neurodegeneration.
Fig. 2. Schematic representation of HSP10/HSP60 complexes in
mitochondria. The HSP10 forms either an asymmetric complex,
assembled by one HSP10 heptameric ring (less efficient complex) (left),
or a symmetric complex, assembled by two rings (right), with HSP60.
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complex results in embryonic lethality [71], and a
heterozygous mutation in the HSPE1 gene, encoding
for HSP10, is associated with a severe, early-onset neu-
rological disorder in humans [72]. Although the
mutant protein retains some functionality, it leads to a
reduction in the HSP10-to-HSP60 ratio. Since a reduc-
tion in the HSP10 levels results in the formation of
asymmetric, less efficient complexes, the levels of client
proteins, such as superoxide dismutase 2 (SOD2),
decreased and, consequently, mitochondrial ROS levels
increase [73]. Therefore, even small changes in the
levels of HSP10 may alter the activity of multiple pro-
teins and cellular functions. In the context of neuro-
logical diseases, the handling of HSP10 levels remains
unclear [72,74–78]. Interestingly, we found that in
either young or middle-aged aSyn transgenic animals,
the levels of mitochondrial HSP10 are reduced, but the
total striatal HSP10 levels were not affected by geno-
type or neither by age. In parallel, the levels of
cytosolic HSP10 were raised in both young and mid-
dle-aged A30PaSyn mice [79]. Spare respiratory capac-
ity (SRC), a measure of mitochondrial activity, is
reduced in synaptosomes from young aSyn transgenic
animals; however, the total mitochondrial fractions are
not affected. Moreover, mitochondrial ROS handling,
mitochondrial membrane potential and the opening of
the mitochondrial permeability transition pore are also
selectively compromised in the synaptic compartment
of the striatum, but not in total mitochondrial frac-
tions [79]. Both synaptosomal and total mitochondrial
SRC are, however, reduced in middle-aged transgenic
mice. These data suggest that age-associated decreased
levels of mitochondrial HSP10 have functional impli-
cations.
Consistently, fractionation of putamen samples from
PD patients and controls revealed that the levels of
synaptosomal HSP10 and SOD2 are reduced in
patients [79]. This causes an increase in mitochondrial
Fig. 3. aSyn interacts with the HSP10 chaperonin in presynaptic terminals. Under physiological conditions, aSyn localizes predominantly in
presynaptic terminals interacting with various proteins (left). The accumulation of toxic aSyn species leads to alterations in synaptic vesicles
and to sequestration of HSP10 in the cytosol, preventing it from acting in the mitochondria (right). These alterations impair mitochondrial
function and result in an increase in ROS and an impairment in ATP production, and ultimately leading to synaptic dysfunction.
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oxidative stress and impairment of respiration, suggest-
ing that HSP10 may be an important player in aSyn-
associated mitochondrial dysfunction in synucle-
inopathies (Fig. 3).
Although there were no changes in soluble aSyn
levels, HSP10 interacts with monomeric, oligomeric
and preformed fibrils (PFFs) of aSyn with affinities in
the micromolar range [79]. Considering that HSP10 is
synthesized in the cytosol and that aSyn is also pri-
marily a cytosolic protein, the primary site for the
interaction between these proteins would be the cyto-
sol. In our study, we showed that pre-incubation of
PFFs with HSP10 reduces the folding activity of the
HSP10/HSP60 complex. However, the folding activity
of complexes already formed does not change [79].
Our study suggests conformation-specific interactions
between aSyn and HSP10, given that we did not
observe effects with aSyn monomers or PFFs.
Restoring the levels of HSP10 reduces
aSyn pathology
As highlighted above, the link between aSyn pathology
and mitochondrial dysfunction in PD is complex. Dys-
functional mitochondria produce less ATP and more
ROS. If this takes place in the synapse, it likely leads
to synaptic dysfunction [80] and, in turn, to the accu-
mulation of aggregated aSyn [81–83] (Fig. 4). Mito-
chondrial health is essential for axonal transport,
regeneration [84] and, consequently, to the clearance
of aSyn [85]. This indicates that enhancing mitochon-
drial health might lead to delayed aSyn pathology
and, as a consequence, to reduced aSyn-associated
mitochondrial dysfunction.
Other chaperones, such as HSP27 [86,87], HSP70
[88–90] and HSP90 [91,92], have already been shown
to play a role in aSyn aggregation and toxicity. Upon
aSyn overexpression, the levels of HSP10 are reduced,
Fig. 4. Model for the interplay between aSyn pathology and mitochondrial dysfunction. The sequestration of HSP10 by aSyn aggregates in
the cytosol leads to mitochondrial impairments. Dysfunctional mitochondria produce less ATP and fail to properly fold mitochondrial
proteins, such as SOD2 levels, leading to an impairment in the elimination of mitochondrial ROS, to a consequent increase in cytosolic ROS
and to impairments in mitochondrial respiration.
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and overexpressing HSP10 restores the detrimental
effects of WTaSyn, such as impairments in mitochon-
drial respiration and ROS handling. In WTaSyn-ex-
pressing cells, HSP10 overexpression results in
increased levels of SOD2 and, consequently, in
improved elimination of mitochondrial ROS. In addi-
tion, the mitochondrial serine protease high tempera-
ture-regulated A2 (HtrA2) levels and SRC are also
normalized, suggesting an overall improvement in
mitochondrial health. Interestingly, overexpression of
HSP10 in cells expressing truncated forms of aSyn,
thought to represent disease-relevant forms, improves
mitochondrial ROS removal, but does not modify
SOD2 and HtrA2 levels, nor does it improve SRC.
This suggests that increasing the levels of HSP10 may
enhance certain aSyn-associated mitochondrial impair-
ments.
HSP10 overexpression also delays the relocalization
of S129-phosphorylated aSyn (paSyn) from neurites
towards the soma, consistently reducing the levels of
insoluble aSyn [79]. These findings were confirmed in
neuronal cells and also in vitro, using the real-time
quaking-induced conversion assay [93,94]. Similarly, in
aSyn transgenic mice, expression of HSP10 restores
the levels of SOD2, decreases ER stress and reduces
aSyn aggregation.
Conclusion
Herein, we provide our viewpoint on the hypothesis of
the accumulation of toxic aSyn-aggregated species in
synapses and axons prior to the onset of cellular
pathologies associated with PD and other LB diseases.
These aSyn aggregates promote neuronal dysfunction
that can result in both intra- and extracellular toxici-
ties. Intracellular mechanisms cause axonal degenera-
tion, which progresses towards the cell body,
eventually leading to neurodegeneration. Extracellular
mechanisms may contribute to the spreading of aSyn
species along synaptic connections and, ultimately, to
the progression of synucleinopathy. Neither of these
mechanisms is fully understood. One hypothesis, which
we put forward, is that aSyn promotes the trapping of
synaptic proteins, such as HSP10, as highlighted in
our recent study. We propose that, like HSP10, other
proteins may also be trapped by aSyn, promoting a
vicious cycle, compromising their normal function
and, thereby, destabilizing the normal neuronal physi-
ology. In fact, and consistently with our viewpoint,
recent studies have demonstrated that LBs may con-
tain a variety of proteins and components that had
not been previously appreciated [95], and that may be
relevant for the alterations that result in neurodegener-
ation. Although we are still missing important infor-
mation to fully understand the molecular mechanisms
involved, studies focused on the idea that aggregated
aSyn species may trap other biomolecules may bring
new ideas that free us from older concepts that have
failed, at least thus far, informing on novel targets that
may lead to future therapies.
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